Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

1.950 +0.040 (+2.09%)
Streaming Delayed Price Updated: 1:29 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Nkarta Posts Narrower Loss in Q2
Via The Motley Fool
Topics Intellectual Property
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
From Nkarta, Inc.
Via GlobeNewswire
NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024
NKTX stock results show that Nkarta beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and market position. 
Via Benzinga
This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Top movers in Thursday's session
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024
NKTX stock results show that Nkarta beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Nkarta restructures to extend its cash runway into 2029, with upcoming NKX019 clinical data readouts in H2 2025. Analysts maintain Buy ratings. 
Via Benzinga
Which stocks are gapping on Thursday?
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
 
Via Benzinga
Why Nkarta Stock Is Soaring Today
One analyst is now more bullish about this clinical-stage biotech stock. 
Via The Motley Fool
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
From Nkarta, Inc.
Via GlobeNewswire
3 Undervalued Stocks Primed for a 2X Return
Discover compelling investment opportunities with top undervalued stocks for high returns leading in healthcare and software. 
Via InvestorPlace
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street’s Radar
Explore these undiscovered stock picks attached with rapid growth in biotechnology, oil and gas, and pharmaceuticals. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.